Histone H3K4 Methyltransferases as Targets for Drug-Resistant Cancers

• Main Authors: Liu Yang, Mingli Jin, Kwang Won Jeong
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Biology
• Subjects: histone H3K4; methyltransferase; resistant cancer; MLLs; inhibitors
• Online Access: https://www.mdpi.com/2079-7737/10/7/581

The KMT2 (MLL) family of proteins, including the major histone H3K4 methyltransferase found in mammals, exists as large complexes with common subunit proteins and exhibits enzymatic activity. SMYD, another H3K4 methyltransferase, and SET7/9 proteins catalyze the methylation of several non-histone targets, in addition to histone H3K4 residues. Despite these structural and functional commonalities, H3K4 methyltransferase proteins have specificity for their target genes and play a role in the development of various cancers as well as in drug resistance. In this review, we examine the overall role of histone H3K4 methyltransferase in the development of various cancers and in the progression of drug resistance. Compounds that inhibit protein–protein interactions between KMT2 family proteins and their common subunits or the activity of SMYD and SET7/9 are continuously being developed for the treatment of acute leukemia, triple-negative breast cancer, and castration-resistant prostate cancer. These H3K4 methyltransferase inhibitors, either alone or in combination with other drugs, are expected to play a role in overcoming drug resistance in leukemia and various solid cancers.